Hans Preusting News Today

Press Release Stockholm, Sweden, December 13, 2023 At the extraordinary general meeting of Mendus AB , reg. no. 556629-1786, , on 13 December 2023 the EGM adopted, inter alia,...

Press Release Stockholm, Sweden, November 13, 2023 The shareholders of Mendus AB , reg. no 556629-1786, are hereby invited to the Extraordinary General Meeting on Wednesday, 13...

Synerkine Pharma, a biopharmaceutical company based in Leiden has successfully secured €5.3M in an extension of its Series A financing. 

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023 Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare Confer...

At the annual general meeting of Mendus AB , reg. no. 556629-1786, on 12 May 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the... | May 12, 2023

08.04.2022 - Press Release Stockholm, Sweden, April 8, 2022 NOTICE OF ANNUAL GENERAL MEETING IN IMMUNICUM AB (PUBL) The shareholders of Immunicum AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the Annual General ...

Synerkine Pharma Raises EUR 3.5 Million in an Extended Series A Financing - read this article along with other careers information, tips and advice on BioSpace